fibrogen, inc. Common Stock ($0.01 par value) Having an Aggregate Offering Price of up to $200 Million Amended and Restated Equity Distribution AgreementEquity Distribution Agreement • February 27th, 2023 • Fibrogen Inc • Pharmaceutical preparations • New York
Reference is made to the Equity Distribution Agreement, dated August 8, 2022 (the “Original Agreement”), by and between FibroGen, Inc., a Delaware corporation (the “Company”) and Goldman Sachs & Co. LLC (the “Existing Manager”).
Letter AgreementLetter Agreement • February 27th, 2023 • Fibrogen Inc • Pharmaceutical preparations
This Letter Agreement (“Letter Agreement”) is effective as of November 4, 2022 (“Effective Date”) by and among Astellas Pharma Inc. (“Astellas”), Astellas Pharma Europe Ltd. (“APEL”), and FibroGen, Inc. (“FibroGen”). This Letter Amendment amends both the Anemia License and Collaboration Agreement entered into by and between Astellas and FibroGen on April 28, 2006, as previously amended (the “EU LCA”) and the Astellas EU Supply Agreement entered into by and between APEL and FibroGen effective as of January 1, 2021, as amended (the “EU CSA”). Astellas, APEL, and FibroGen shall be referred to individually herein as a “Party” and collectively as the “Parties”.
SAMSUNG BIOLOGICS CO., LTD. AMENDMENT NO 1 TO PRODUCT SPECIFIC AGREEMENT – CLINICAL PRODUCT DRUG SUBSTANCEProduct Specific Agreement – Clinical Product Drug Substance • February 27th, 2023 • Fibrogen Inc • Pharmaceutical preparations
This Amendment No. 1 to the Product Specific Agreement – Clinical Product Drug Substance (this “Amendment No. 1”) is made effective as of the date of last signature below (the “Amendment No. 1 Effective Date”) by and between FibroGen, Inc., a Delaware corporation having its principal place of business at 409 Illinois Street, San Francisco, California, USA 94158 (“Client”) and Samsung Biologics Co., Ltd., a Korean corporation having its principal place of business at [*] (“SBL”). Client and SBL are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
Revenue Interest Financing AgreementRevenue Interest Financing Agreement • February 27th, 2023 • Fibrogen Inc • Pharmaceutical preparations • New York
This Revenue Interest Financing Agreement (this “Agreement”) is entered into as of November 4, 2022 (the “Effective Date”), between FibroGen, Inc., a Delaware corporation having an address of 409 Illinois Street, San Francisco, CA 94158 (“Company”) and NQ Project Phoebus, L.P., a Delaware limited partnership having an address of 4208 Six Forks Road, Suite 920 Raleigh, NC 27609 (“NovaQuest”). Company and NovaQuest are each referred to herein by name or, individually, as a “Party” or, collectively, as “Parties.”
